Peer-reviewed veterinary case report
Olsalazine slows growth and DNA changes in dog lymphoid tumor cells
By Itoh, S et al.·Published in Polish journal of veterinary sciences·2021·Azabu University, Japan·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Olsalazine inhibits cell proliferation and DNA methylation in canine lymphoid tumor cell lines.
- Species:
- dog
Plain-English summary
A study found that olsalazine, a medication derived from salicylic acid, can help treat lymphoid tumors in dogs by slowing down the growth of cancer cells. When tested on canine lymphoid tumor cell lines, olsalazine significantly reduced cell growth and increased the rate of cell death. It also decreased abnormal DNA methylation, which is linked to cancer progression. This suggests that olsalazine could be a promising option for chemotherapy in dogs with lymphoid tumors.
People also search for: dog lymphoid tumor treatment · olsalazine for dog cancer · canine lymphoma chemotherapy options
Abstract
Abnormal DNA methylation is involved in the initiation and progression of lymphoid tumors. Hence, DNA demethylating agents are promising candidate drugs for chemotherapy against these tumors. The salicylic acid derived anti-inflammatory agent, olsalazine, reportedly suppresses DNA methyltransferase in human cells and has the potential to be clinically applied as a DNA demethylating agent. In this study, we investigated the effects of olsalazine on cell proliferation and DNA methylation using canine lymphoid tumor cell lines (CLBL-1, GL-1, and UL-1). Treatment with olsalazine led to significant cell growth inhibition and increased the apoptotic rate in all three cell lines. Treatment with olsalazine reduced the total amount of 5-methylcytosine in genomic DNA, as assessed by enzyme-linked immunosorbent assay. Genome-wide analysis of DNA methylation revealed that 1,801 to 5,626 CpG sites showed decreased DNA methylation levels in three cell lines, including the promoter regions of ADAM23, FES, and CREB3L1 genes. The outcomes of the present study demonstrate that a DNA demethylating agent olsalazine, inhibits cell proliferation and DNA methylation in canine lymphoid tumor cells, suggesting that it can be a candidate drug for the treatment of lymphoid tumors in dogs.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/35179837/